The industry of healthcare has made huge strides over the years if you look at the innovation that has taken place. You’re seeing a massively accelerated pace of this technological development. I think that the word disruptive is a word that’s synonymous with healthcare today. Most of the scientists we work with describe a 10 to 15 year arc to solving these really serious diseases like cancer and muscular dystrophy and a host of others. It’s a very exciting time, a very dynamic time but one with a lot of disparate factors that are all at play. At J.P. Morgan, we know the industries well; we know the trends, we know what institutional investors are going to be looking for. J.P. Morgan has a long history in working with and advising healthcare companies within the Life Sciences industry. These are people working in very complex areas of science and they’re about to make a scientific discovery that is going to impact millions and millions of people for positive reasons. One of the reasons we started the Life Sciences practice is we saw a need in the sector, in the community, in the market, for this type of advice. We focu so that our clients can focus on the things that they’re really good at. What they really want is a partner that understands what they do This is really the only effort that I know of to dedicate a full banking effort around ‘what does the company do’. How do I manage my own personal wealth? How do I expand overseas? Start thinking about an exit down the road? All of those different aspects we can help with. I’ve been at J.P. Morgan for 20 years and the reason that I’ve been here for as long as I have is really what J.P. Morgan brings to the table. It’s our depth of the expertise we have and the seamless coordination that we have with the other lines of business. Whether it’s our partners in the Investment Bank, our partners in the Commercial Bank, or within the Private Bank being able to work with a client and their company across their entire life cycle – from start to finish – is really one of the biggest key strengths that we see for entrepreneurs and for companies. One of the challenges we see in the market right now is entrepreneurs will come to us and say, “I’m not ready for J.P. Morgan yet. We’re too small.” You might be small in size, which a lot of Life Sciences companies are, but it doesn’t mean that you’re small in potential. There are many different aspects to the Life Sciences community where you’re first reaction is, “How do I help this company?” Being able to help companies along this journey to do something that’s truly life changing I think it’s one of the things that drives our people that are focused on this space to go above and beyond. What makes J.P. Morgan different is that we work really collaboratively. And every day it’s about building each other up and being a single J.P. Morgan to our clients across the entire bank. Clients trust J.P. Morgan because we are more than just an investment manager for them, we’re their partner. When a client has that ultimate success, whether it’s FDA approval, the sale of their company or an IPO, being able to share in the success and know that we gave them the sleep at night is one of the greatest points of satisfaction in our role.